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Assessment of the clinical presentation  
and factors affecting the natural history  
of typical atrioventricular nodal reentrant tachycardia
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Abstract
Introduction. Atrioventricular nodal reentrant tachycardia (AVNRT) is the most common regular tachyarrhythmia; 
however, its clinical presentation has not been investigated in detail. The aim of the study was to assess the clinical 
presentation and identify the potential factors significantly affecting the natural history of AVNRT in patients undergoing 
RF ablation.
Material and methods. Ninety-two consecutive patients with invasive diagnosis of typical AVNRT who underwent RF 
ablation were included. All patients were actively screened for the presence of structural heart disease (SHD). The re-
trospective, arrhythmia focused interviews regarding its clinical history, affecting factors and treatment were conducted. 
The medical records and tachycardia ECG tracings data were included, if available.
Results. Seventy-five percent of patients had evidence of the arrhythmia exacerbation. No relationship between the 
coronary (66%) or brain (33%) hypoperfusion symptoms and clinical factors was found. Time to the tachycardia diagno-
sis was significantly longer in women (13 ± 11 vs 7 ± 8 years, p = 0.006). Pharmacological AVNRT management was 
not consistent with the ESC guidelines. The arrhythmia symptoms were occurring later if SHD was present (44 ± 13 
vs 30 ± 5 years, p = 0.001). The longer AVNRT cycle length (CL), modified by the age when symptoms appeared and 
the presence of impaired myocardial contractility, the longer time to the arrhythmia diagnosis and exacerbation. Mitral 
valve prolapse (MVP) was more common in female patients compared with the general population and was found to 
be the factor delaying AVNRT diagnosis.
Conclusions. In the majority of patients AVNRT exacerbation takes place. The coronary and brain hypoperfusion symp-
toms that patients often experience are nonspecific. There is a significant delay in the arrhythmia diagnosis, especially 
in women. SHD, AVNRT CL and MVP were identified as factors that significantly modify the arrhythmia clinical presen-
tation.
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Introduction
Atrioventricular nodal reentrant tachycardia (AVNRT) is 
the most common regular tachyarrhythmia, affecting 
2–5/1000 adults [1, 2] and accounting for 50–60% of 
all regular tachyarrhytmias [3, 4]. Most researchers focus 
on the assessment of electrophysiological characteristics 
of AVNRT, whereas its clinical presentation has not been 
thoroughly investigated.
The aim of the study was to assess the clinical pre-
sentation and identify the potential factors significantly 
affecting the natural history of AVNRT in patients under-
going RF ablation.
Material and methods
Overall, 92 consecutive patients (59 women and 33 men 
aged 46.6 ± 17.6 years) with diagnosis of typical AVNRT 
confirmed with electrophysiology study (EPS) who under-
went one-stage RF ablation in the years 2006–2009 were 
included in the study. The study received the approval of 
local Ethics Committee and informed written consent has 
been obtained from all participants prior to the study. 
All patients were actively screened for the presence of 
structural heart disease (SHD) based on medical history 
and physical examination, 12-lead electrocardiography 
(ECG) and transthoracic echocardiography (TTE), followed 
by additional cardiac diagnostic tests, if needed. Table 1 
presents clinical entities that are categorised as SHD. The 
retrospective, arrhythmia focused interviews regarding 
its clinical history, affecting factors and treatment were 
conducted. The medical records were also included, if 
available. Pain or discomfort in the chest were considered 
as symptoms indicative of coronary hypoperfusion, whereas 
brain hypoperfusion was suspected if following symptoms 
were present: syncope, blurred vision, scotomas, mumbling 
speech, muscle weakness in extremities, and tingling/ 
/sensory disturbances in the face. Arrhythmia exacerbation, 
i.e. the moment from which arrhythmia episodes became 
more frequent and/or of longer duration, was established 
based on patient’s subjective assessment. Mean frequen-
cy, duration and tolerance of arrhythmia episodes were also 
assessed by patients. The analysis included 12-lead ECG 
recordings with tachyarrhythmia performed prior to EPS 
(91% of patients). The assessment of 2003 ESC guidelines 
implementation [1] in terms of emergency and long-term 
therapies was limited to patients in whom the symptoms 
of arrhythmia occurred after these guidelines were issued 
(93% of patients).
Statistical analysis
Analyses were performed using STATISTICA 8™ software 
(StatSoft Inc.). Data are presented as arithmetic means 
and standard deviation (± SD). Distribution normality 
was established with Shapiro-Wilk test. Between-group 
Table 1. Prevalence of structural heart disease and most common concomitant diseases
No Structural heart disease Number of patients
1 Arterial hypertension complicated by myocardial hypertrophy* 11 (42%)
2 Coronary heart disease** without previous myocardial infarction 8 (31%)
3 Coronary heart disease** with previous myocardial infarction 6 (19%)
4 Significant aortic valve disease*** 4 (16%)
5 Patent foramen ovale with high left-to-right shunt**** 2 (8%)
6 Dilated cardiomyopathy 2 (8%)
7 Chronic heart failure NYHA class ≥ II 2 (8%)
8 Significant mitral valve disease*** 2 (8%)
9 Sinus node dysfunction demanding pacemaker implantation 1 (4%)
10 Haemodynamically significant interatrial septal defect**** 1 (4%)
The most common concomitant diseases besides structural heart disease
1 Mitral valve prolapse without valvular insufficiency 26 (45%)
2 Stage I hypertension according to WHO 15 (26%)
3 Thyroid diseases 8 (14%)
4 Atrial fibrillation and/or flutter 8 (14%)
*Based on left ventricular mass index; **confirmed by angiography; ***insufficiency or stenosis assessed by echocardiographist as moderate or severe; ****based on transoesophageal echocar-
diography; NYHA — New York Heart Association; WHO — World Health Organization
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comparisons were performed using U Mann-Whitney, 
Wilcoxon, Pearson’s chi-square and McNemara’s chi-
-square tests. Correlation analysis was performed based on 
Pearson’s linear correlation. P values < 0.05 were conside-
red statistically significant. Statistical power was estimated 
for every test, assuming that acceptable value is ≥ 0.8.
Results
Onset of arrhythmia symptoms
First symptoms of arrhythmia occurred at the age of 34 
± 18 years (median ± interquartile range 51 ± 21 years); 
the variable distribution followed non-normal pattern 
(p < 0.0001), with marked peak in the second decade of 
life (30%). In 84% of patients arrhythmia occurred before 
the age of 40. It has been observed that arrhythmia symp-
toms occurred significantly later in patients with structural 
heart disease (44 ± 13 vs 30 ± 5 years, p = 0.001) and 
significant moderate negative correlation was observed 
with left ventricular ejection fraction (LVEF) (p < 0.0001).
Structural heart disease  
and other concomitant diseases
SHD was diagnosed in 28% of patients and in 30% of these 
patients 2 or more clinical entities were present. Sixty-three 
percent of patients have at least one of 11 concomitant 
diseases (Tab. 1).
Symptoms and provoking factors of AVNRT
Patients reported 23 different symptoms experienced du-
ring arrhythmia episode (Tab. 2). No relations were shown 
between possible symptoms of coronary (66% of patients) 
or brain (33% of patients) hypoperfusion and tachycardia 
cycle length (CL), presence of SHD and patients’ age 
(p > 0.05). Overall, 89% of patients have identified 13 fac-
tors provoking arrhythmia (Tab. 2), but in 75% of them there 
were also idiopathic episodes of arrhythmia that occurred 
mostly during the day (100%), while performing usual daily 
activities (86%) or resting (34%), and more rarely during the 
night (36%). No patient noticed any differences between 
arrhythmia episodes in terms of heart rate.
Arrhythmia exacerbation
Arrhythmia exacerbation was observed in 75% of pa-
tients in whom arrhythmia episodes became significantly 
more frequent (0.3 ± 0.4/months vs 8 ± 19/months, 
p < 0.0001) and significantly longer (38 ± 53 minutes vs 
254 ± 365 minutes, p < 0.0001), whereas in 25% of pa-
tients the frequency and duration of arrhythmia episodes 
remained unchanged (3 ± 3/year and 48 ± 55 minutes). 
Table 2. Most common symptoms and provoking factors of atrioventricular nodal reentrant tachycardia (AVNRT)
No Most common symptoms of AVNRT Number of patients
1 Paroxysmal palpitations 79 (89%)
2 Asthenia 76 (83%)
3 Fatigability (reduced exercise tolerance) 70 (76%)
4 Dyspnoea 63 (68%)
5 Retrosternal pain and/or discomfort in the chest 61 (66%)
6 Dizziness 58 (63%)
7 Anxiety, irritability 55 (60%)
8 Urination during/after arrhythmia episode 27 (29%)
9 Blurred vision/scotomas 23 (25%)
10 Syncope 18 (20%)
11 Tingling/sensory disorders in the face 5 (5%)
12 Mumbling speech 4 (4%)
13 Considerable muscle weakness in extremities (paresis) 2 (2%)
Most common provoking factors of AVNRT episodes
1 Intense physical exercise 41 (45%)
2 Stress and/or emotion 37 (40%)
3 Sudden change of body position 34 (37%)
4 Sleeping (the patient woke up due to arrhythmia episode) 17 (18%)
5 Sudden change of ambient temperature (sauna, going outside in cold weather) 8 (9%)
6 Menstruation 8 (14% of women)
7 Pregnancy 1 (2% of women)
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Time from first symptoms to exacerbation of arrhythmia was 
14 ± 11 years. The duration of this period was significantly 
related to AVNRT CL — the longer arrhythmia CL, the longer 
time to exacerbation (Tab. 3). Symptom exacerbation was 
observed significantly more frequent in patients recei-
ving oral drugs for arrhythmia prevention (84% vs 52%, 
p = 0.002), regardless the duration of treatment (p > 0.05). 
No relationship between arrhythmia exacerbation and pa-
tients’ age was found (46 ± 16 vs 42 ± 12 years, p > 0.05).
Tachycardia tolerance
Good tolerance of tachycardia was found to be significantly 
more frequent in patients without tachycardia exacerbation 
(p = 0.045), dyspnoea (p = 0.004), blurred vision/scotomas 
(p = 0.02) or syncopes (p = 0.01) and in patients without 
provoked arrhythmia episodes during day- or night-time 
(p = 0.03). It was also more frequent during the rest 
(p = 0.02) and in patients who did not receive pharmacolo-
gical SVT prevention (p = 0.02). There was no relationship 
between tachycardia tolerance and the presence of SHD, 
AVNRT CL and episode duration (p > 0.05). EPS did not 
reveal poor haemodynamic AVNRT tolerance in any patient.
Diagnosis of paroxysmal tachycardia
In 66% of cases SVT diagnosis was established at admis-
sion, in emergency room, or during hospitalization. In 20% 
of patients SVT was diagnosed by rescue crew, in 12% — by 
a GP practitioner, and in 2% — by a specialist in a cardiology 
clinic. The diagnosis was made based on 12-lead ECG (86%), 
24-h Holter ECG (5%), transoesophageal stimulation (1%) 
or during EPS (8%). Eighty-five percent of patients repor-
ted that at least once the symptoms subsided before ECG 
recording. In 35% of patients 24-h ECG was performed 
and SVT was recorded in 28% of them (10% of all ana-
lysed patients). Time from first occurrence of arrhythmia 
symptoms to diagnosis of SVT was 11 ± 10 years. Only in 
12% of patients the diagnosis was established during the 
first arrhythmia episode. Table 4 presents interpretation of 
symptoms and physician’s recommendations prior to the 
diagnosis of paroxysmal SVT, based on medical records and 
patient interview. Time to diagnosis was significantly longer 
in women when: the arrhythmia episode was provoked by 
emotion (13 ± 9 vs 9 ± 11 years, p = 0.008); the symptom 
of an episode was the necessity of urination (13 ± 10 vs 10 
± 10 years, p = 0.03), and the patient did not experience 
Table 3. Analysis of the relationships between clinical factors and atrioventricular nodal reentrant tachycardia (AVNRT) cycle length (CL)
Clinical factor Yes No P value
Palpitations 345 ± 50 ms 400 ± 55 ms 0.001
Symptom onset at the age of ≥30 361 ± 50 ms 337 ± 56 ms 0.01
Significant ST depression during tachycardia 318 ± 42 ms 363 ± 52 ms 0.001
Impaired myocardial contractility 396 ± 47 ms 347 ± 52 ms 0.01
Correlation r p
Age at the onset of arrhythmia 0.3 0.006
Time from symptom onset to diagnosis of SVT 0.2 0.07
Time from symptom onset to arrhythmia exacerbation 0.3 0.03
SVT — supraventricular tachycardia
Table 4. Interpretation of reported symptoms and physician’s recommendations
No Potential cause of the symptoms Number of patients
1 Coronary heart disease — cardiology consultation 29 (32%)
2 Mitral valve prolapse syndrome — follow-up 25 (27%)
4 Thyroid disease — endocrinology consultation 21 (23%)
5 Puberty — follow-up 21 (23%)
6 Perimenopausal period — gynaecology consultation 19 (32% of women)
7 Paroxysmal arrhythmia had resolved before the registration — 24-h ECG 17 (18%)
8 Smoking — smoking cessation 17 (18%)
9 Neurosis — sedatives 16 (17%)
10 Exacerbation of concomitant diseases — specialist consultation 11 (12%)
11 Electrolyte disturbances — K+ and Mg2+ supplementation 2 (2%)
ECG — electrocardiogram
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dizziness (14 ± 11 vs 9 ± 10 years, p = 0.03). Moreover 
it has been observed that the longer arrhythmia CL, the 
longer the time to diagnosis (Tab. 3).
Emergency and long-term medications
Pharmacological agents for prevention of SVT were used in 
79% patients, often several drugs in monotherapy (Tab. 5). 
Only in 7% of these patients no SVT episodes were noted 
during subsequent follow-up. Mean treatment duration 
was 2.3 ± 4.2 years. Vagal manoeuvres, i.e. Valsalva ma-
noeuvre and/or carotid sinus massage, were performed 
only by medical staff. Patients were not recommended to 
use them by oneself for stopping the arrhythmia. Methods 
of arrhythmia termination are presented in Table 6.
Analysis of the relationship  
between clinical factors and sex
Women were more prevalent in the study group (64%). The 
analysis of the relationship between clinical factors and sex 
is presented in Table 7.
Analysis of 12-lead ECG recordings  
with tachycardia
Ventricular CL during arrhythmia was 351 ± 53 ms (ran-
ge 240–500 ms) and did not differ significantly from CL 
observed during EPS. Some factors significantly modified 
AVNRT CL thereby influencing the course of tachycardia 
(Tab. 3). In 25% of recordings, significant ST segment 
depression was observed during AVNRT (horizontal or 
downsloping > 1 mm), and in 6% of cases there was ST seg-
ment depression with T-wave inversion, absent in resting 
ECG. No relationship was found between the presence of 
ST-T abnormalities during tachycardia and clinical factors 
(p > 0.05), except for arrhythmia CL.
Discussion
It has been confirmed that AVNRT may occur at any age, 
most often before 40 [1, 4]. Previously unreported later 
occurrence of tachycardia in patients with SHD should be 
noted. It can be assumed that the presence of SHD resulted 
in modified electrophysiological properties of atrioventri-
cular junction (AVJ) anisotropic area thereby temporarily 
Table 5. Oral drugs used for SVT prevention
Medication Number of patients
β-blocker 47 (70%)
Verapamil 19 (28%)
Propafenone 11 (16%)
Amiodarone 5 (7%)
Sotalol 5 (7%)
K+/Mg2+ supplementation 6 (9%)
Mexiletine 1 (1%)
Quinidine 1 (1%)
SVT — supraventricular tachycardia
Table 6. Methods of emergency management of supraventricular tachycardia (SVT) and their effectiveness
Methods of SVT termination Number of patients Overall number  
of interventions
Effective Ineffective
Vagal manoeuvre 23 (25%) 23 6 (26%) 17 (74%)
Electrical cardioversion 4 (4%) 4 4 (100%) 0
Intravenous drug 85 (92%) 140 134 (96%) 6 (4%)
Verapamil 50 (36%) 50 (100%) 0
Adenosine 34 (24%) 33 (97%) 1 (3%)
β-blocker 29 (21%) 26 (90%) 3 (10%)
Amiodarone 17 (12%) 15 (88%) 2 (12%)
Propafenone 10 (7%) 10 (100%) 0
Pill-in-the-pocket 14 (15%) 18 18 (100%) 0
Verapamil 7 (39%) 7 (100%) 0
β-blocker 6 (33%) 6 (100%) 0
Propafenone 3 (17%) 3 (100%) 0
Amiodarone 1 (6%) 1 (100%) 0
Sotalol 1 (6%) 1 (100%) 0
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precluding the formation of persistent reentry circuit in 
‘electrophysiologically predisposed’ subjects in whom 
arrhythmia hasn’t manifested yet. On the other hand, the 
development of heart disease, usually at middle or older 
age, might have been a provoking factor for AVNRT, crea-
ting an appropriate background for it. Modification of AVJ 
area by SHD might have resulted from autonomic system 
changes in this area [4]. This may indirectly indicate the 
impact of impaired myocardial contractility on AVNRT CL.
In the study group, the percentage of patients with SHD 
was higher than that reported in the literature, where it 
was usually less than 15% [5, 6]; although, in older papers 
heart disease, mainly hypertensive-ischaemic type, was 
observed in 31–45% of patients [7]. The number of these 
patients depends of the age of the analysed population 
[7], although in our opinion the most important issue is 
unclear, and often subjective, definition of SHD.
Reported symptoms and provoking factors of tachy-
cardia confirm that usually there are no specific clinical 
symptoms pathognomonic for AVNRT. Coronary and brain 
hypoperfusion symptoms are rarely described (< 3%), ma-
inly in elderly patients, although less specific symptoms 
suggesting organ ischaemia, e.g. discomfort in the chest, 
are more frequent (40%) [1, 3, 5–9]. In our study, symptoms 
indicative of coronary or brain hypoperfusion were observed 
more frequently. Due to the fact that the presence of this 
symptoms was not associated with AVNRT CL, SHD and 
patients’ age, the percentage of patients with tachycardia 
(4%) who required electric cardioversion was low, and there 
were no reports on poor haemodynamic tolerance during 
EPS, the diagnosis of actual ischaemia of central nervous 
system or myocardium during AVNRT seems to be unlikely. 
Table 7. Analysis of the relationship between clinical factors and sex
Clinical factor W M P value
Structural heart diseases 12 (20%) 14 (42%) 0.02
Coronary heart disease with previous myocardial infarction 1 (2%) 5 (15%) 0.04
Concomitant diseases 43 (73%) 15 (45%) 0.009
Mitral valve prolapse (MVP) 23 (39%) 3 (9%) 0.005
Differential diagnosis: neurosis 14 (24%) 2 (6%) 0.06
Differential diagnosis: MVP 24 (41%) 4 (15%) 0.01
Differential diagnosis: coronary heart disease 8 (14%) 17 (52%) 0.0001
Symptoms of arrhythmia: anxiety, irritability 45 (76%) 10 (30%) < 0.0001
Arrhythmia provocation by intense exercise 20 (34%) 21 (64%) 0.006
Arrhythmia provocation by emotion 29 (49%) 8 (24%) 0.002
Time from symptom onset to diagnosis of SVT (years) 13 ± 11 7 ± 8 0.006
Age at onset of symptoms (years) 32 ± 17 38 ± 19 0.09
LVEF (%) 62 ± 5 58 ± 8 < 0.0001
Frequency of episodes (n/year) before SVT exacerbation 2.6 ± 4.9 3.6 ± 3.8 0.02
SVT — supraventricular tachycardia; W — women; M — men
The nature of reported symptoms may be attributed to 
patients’ individual sensitivity to tachycardia; therefore, 
differential diagnosis of syncope (20%) should include 
other potential reasons, besides AVNRT.
A new observation is that AVNRT exacerbation occurs 
in the majority of patients (75%) about 14 years after the 
symptom onset. The reason of this phenomenon remains 
unclear. Shorter AVNRT CL found to be a predictor for subse-
quent exacerbation of the arrhythmia. Marked association 
between arrhythmia exacerbation and pharmacological 
prevention of arrhythmia episodes is unequivocal. It may 
result from proarrhythmic effect of drugs taken. The most 
frequently used drugs, β-blockers and verapamil, affecting 
slow pathway of atrioventricular node, may prevent AVNRT 
recurrence, but in some patients they have opposite effect. 
Other researchers identified a phenomenon of sponta-
neous regression of arrhythmia symptoms, which was not 
observed in our study. In a study performed by D’Este et al. 
[6], 45% out of 38 untreated patients with AVNRT remained 
asymptomatic during recent 3 years of long-term follow-up. 
Prior to inclusion, these patients had significantly shorter 
history of arrhythmia; episodes occurred less frequently 
and were of shorter duration. This was not, however, a ran-
domised trial, and the arrhythmia symptom regression had 
not been verified based on lack of AVNRT induction during 
EPS. It cannot be excluded that symptom recurrence might 
have been observed later, if the patients were followed-up 
longer. The authors speculate that the phenomenon of 
arrhythmia ‘disappearance’ may have been caused by the 
fact that electrophysiological properties of the element of 
reentry circuit change with time [6]. The frequency and 
duration of AVNRT episodes remained unchanged in long-
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It has been confirmed that AVNRT is more prevalent in 
women (60–78%), in whom arrhythmia develops at 10 ye-
ars younger age, and has different clinical history than in 
men [1, 3–5, 8, 9, 13]. In women, SHD (related to later 
manifestation of tachycardia), including coronary heart 
disease and reduced LVEF, occurs more rarely, which might 
be attributed to patient age distribution. Coronary heart 
disease becomes more prevalent in women than in men 
only after the age of 70 [14]. A new finding is more frequ-
ent occurrence of MVP in patients with AVNRT compared 
with general population (4–17%). MVP is more common in 
women between 20 and 40 years of age; it is often asso-
ciated by impaired autonomic and neuroendocrine control 
leading to, among others, increased catecholamine levels. 
This mechanism may potentially affect electrophysiologi-
cal properties of AVJ, enabling the formation of a critical 
reentry circuit for AVNRT, and numerous premature atrial 
complexes may lead to arrhythmic episode [15]. This may 
be the cause of more common occurrence of AVNRT in 
women. It has been confirmed that time to establishing 
diagnosis of paroxysmal SVT is considerably longer in fe-
male patients [16]. Main reason for the delay in diagnosis 
is misinterpretation of arrhythmia symptoms, particularly 
as related to neurosis, MVP and perimenopausal period or 
exacerbation of more common concomitant diseases. Furt-
hermore, significant impact on increased time to diagnosis 
had also the presence of women-specific provoking factors 
(emotion), symptoms of AVNRT (anxiety, irritability) and lo-
wer frequency of episodes before arrhythmia exacerbation. 
Moreover, symptoms concomitant with MPV and provoking 
circumstances are very similar to those of paroxysmal SVT 
[15]. It seems that more frequent provocation of AVNRT by 
physical exercise and suspected coronary heart disease in 
men sped up establishing of proper diagnosis.
More frequent ST-T abnormalities during arrhythmia 
were observed, that were dependent on AVNRT CL and un-
related to coronary heart disease and symptoms suggesting 
myocardial ischaemia. It seems that these abnormalities 
are functional in nature and are not associated with myo-
cardial ischaemia [17].
Limitations of the study
Patients included in the study were not consecutive pa-
tients with arrhythmia selected from general population, 
but subjects with AVNRT, who decided to underwent abla-
tion. Those who refused to undergo invasive diagnostics 
for SVT and paediatric patients were excluded from the 
study. Probably, patients with more advanced disease, 
who are more prone to underwent invasive procedures, 
were overrepresented in the study group. Additionally, 
history data collected based on patient interview are 
subjective and usually cannot be verified. This may partly 
-term follow-up, until ablation. Maybe in those patients 
spontaneous symptom regression would also be observed, 
if the follow-up period was extended.
The tolerance of tachycardia is determined mostly by 
the presence of SHD, AVNRT CL and episode duration as 
well as patient’s individual sensitivity to arrhythmia [1, 3, 
10]. In this paper, it was found that the tolerance of AVNRT 
symptoms was related only to episode exacerbation and 
individual sensitivity to tachycardia expressed by the lack 
of some symptoms and/or provoking factors. One of the 
reasons for the discrepancy of published data may be 
different range of diseases categorised as SHD [5, 7, 8]. 
Additionally, the study population might have been too 
small, which translated to lower number of patients with 
advanced heart disease. Overrepresentation of patients 
with arrhythmia exacerbation is also possible.
Significant delay in establishing the diagnosis of 
arrhythmia has been observed, which seems to have mul-
tifactorial background. Paroxysmal, unpredictable nature 
of AVNRT caused considerable problems with its recording. 
Long-term monitoring techniques recommended by current 
guidelines [1] have not been used (event recorders, ECG 
telemetry) or were rarely used (Holter ECG). Moreover, 
non-specific symptoms and circumstances of AVNRT provo-
cation were misinterpreted by a medical staff, particularly 
in women. For the first time, it has been observed that 
longer AVNRT CL (the parameter that depends on age at 
symptom onset and the presence of impaired myocardial 
contractility) is related to delayed SVT diagnosis. This 
relationship seems to be determined by lower frequency 
of palpitations (Tab. 3).
Lower than reported in the literature effectiveness 
of pharmacotherapy in the prevention of SVT episodes, 
estimated to be 30–50% [1, 11], results probably from 
the range of antiarrhythmic agents used and frequent use 
of drugs that were not recommended [1]. The methods 
used for AVNRT episode termination were inconsistent with 
current guidelines recommendations [1]. Despite relevant 
high-class recommendations, vagal nerve manoeuvres 
and drugs characterized with the highest effectiveness 
(adenosine, diltiazem, verapamil) [5] were rarely performed 
or advised and, even more, drugs that are not recommen-
ded were used (e.g. amiodarone) [1]. Ranges of used 
antiarrhythmic drags may have been determined by their 
availability. It is not without significance that basic ambu-
lance crew composed of medical rescuers is allowed to 
administer only 2 antiarrhythmic drugs, i.e. amiodarone and 
lignocaine [12]. Also the drugs used as pill-in-the-pocket 
strategy were inconsistent with the guidelines [1], although 
all of the drugs used proved to be effective. It should be 
noted that, although current guidelines recommend the 
use of single oral dose or diltiazem or propranolol, such 
treatment has not been used in the study patients.
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explain the differences observed when compared with 
literature data.
Conclusions
In this study, it has been found that exacerbation of 
episodes of typical AVNRT in a group of patients who 
underwent ablation occurred in the majority of patients, 
which influence the tolerance of arrhythmia symptoms, 
and that frequently reported by patients symptoms of 
coronary and brain hypoperfusion were unspecific. Furt-
hermore, considerable delay in diagnosis of arrhythmia 
was observed, particularly in women, which was at least 
in part dependent on medical staff (misinterpretation 
of symptoms, ECG recording methods used). Moreover, 
emergency and long-term pharmacotherapy of AVNRT was 
inconsistent with therapeutic guideline recommendations. 
Also, potential factors significantly influencing natural 
history of AVNRT has been identified. It has been found 
that SHD is related to later development of tachycardia 
and AVNRT occurrence at younger age in women. AVNRT 
CL (a parameter that is dependent on the age at arrhyth-
mia occurrence and the presence of impaired myocardial 
contractility) influences many factors such as time to 
establishing the diagnosis of SVT and to exacerbation of 
arrhythmia, the presence of palpitations or ST-T abnorma-
lities during tachycardia. More frequent presence of MVP 
in women with AVNRT compared with general population 
is one of factors causing delay in diagnosis SVT due to 
misinterpretation of the symptoms of arrhythmia that are 
attributed to MVP. This may also be the reason why AVNRT 
is more common in women.
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Streszczenie
Wstęp. Nawrotny częstoskurcz węzłowy (AVNRT) jest najczęstszą regularną tachyarytmią, ale obraz kliniczny częstoskur-
czu nie został dotychczas szczegółowo zbadany. Celem pracy była ocena przebiegu klinicznego i identyfikacja potencjal-
nych czynników mających istotny wpływ na historię naturalną typowej postaci AVNRT u chorych poddawanych ablacji.
Materiał i metody. Do badania włączono 92 kolejne osoby z rozpoznanym podczas badania elektrofizjologicznego 
typowym AVNRT, poddane ablacji podłoża arytmii. U wszystkich pacjentów aktywnie poszukiwano obecności choroby 
organicznej serca (SHD). Zebrano celowany, retrospektywny wywiad dotyczący przebiegu arytmii, wpływających na niego 
czynników oraz stosowanego leczenia, z uwzględnieniem dostępnej dokumentacji medycznej i zapisu elektrokardiogra-
ficznego z obecnością AVNRT.
Wyniki. U 75% pacjentów wystąpiło nasilenie arytmii. Nie wykazano zależności zgłaszanych objawów hipoperfuzji 
wieńcowej (66%) i mózgowej (33%) od czynników klinicznych. Czas do rozpoznania częstoskurczu był dłuższy u kobiet 
(13 ± 11 v. 7 ± 8 lat; p = 0,006). Leczenie farmakologiczne AVNRT odbiegało od zalecanych wytycznych postępowania. 
Objawy arytmii pojawiały się później w obecności SHD (44 ± 13 v. 30 ± 5 lat; p = 0,001). Dłuższa długość cyklu (CL) 
AVNRT, na którą wpływał wiek pojawienia się objawów i obecność zaburzeń kurczliwości mięśnia sercowego, wydłużała 
czas do rozpoznania i nasilenia arytmii. Wypadanie płatka zastawki mitralnej (MVP) występowało u pacjentek częściej 
w porównaniu do populacji ogólnej i było czynnikiem opóźniającym rozpoznanie AVNRT.
Wnioski. Nasilenie napadów AVNRT następuje u większości pacjentów. Często zgłaszane objawy hipoperfuzji wieńcowej 
i mózgowej mają niespecyficzny charakter. Ma miejsce znaczne opóźnienie rozpoznania arytmii, zwłaszcza u kobiet. 
Strukturalna choroba serca, AVNRT CL i MVP stanowią czynniki istotnie modyfikujące przebieg częstoskurczu.
Słowa kluczowe: częstoskurcz węzłowy nawrotny, choroba organiczna serca, nasilenie arytmii
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